A multi-center randomized, parallel-group, double-blind, placebo-controlled study of XP19986 in subjects with symptomatic gastroesophageal reflux disease (GERD)
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2016
At a glance
- Drugs Arbaclofen placarbil (Primary)
- Indications Gastro-oesophageal reflux; Heartburn
- Focus Therapeutic Use
- Sponsors XenoPort
- 26 Apr 2011 Results published in the American Journal of Gastroenterology.
- 27 Oct 2010 Safety results were presented at the 18th United European Gastroenterology Week.
- 05 May 2010 Pharmacokinetic/pharmacodynamic results have been presented at Digestive Disease Week (DDW) 2010.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History